Rapid Micro Biosystems, Inc. (RPID)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rapid Micro Biosystems, Inc. (“Rapid Micro” or the “Company”) (NASDAQ: RPID). Investors who purchased Rapid Micro shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Rapid Micro and certain of its officers and/or directors have violated federal securities laws and breached fiduciary duties.
On January 9, 2022, Rapid Micro issued a press release announcing its preliminary unaudited financial results for the fourth quarter and full year 2021, along with commercial revenue outlook for 2022. Among other items, Rapid Micro reported that it currently expects total revenue between $22.8 million and $23.3 million for 2021, falling well short of consensus estimates. On this news, Rapid Micro’s stock price fell $1.94 per share, or 21.23%, to close at $7.20 per share on January 10, 2022.
If you are aware of any facts relating to this investigation or purchased Rapid Micro shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.